HUP0001528A2 - Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére - Google Patents

Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére

Info

Publication number
HUP0001528A2
HUP0001528A2 HU0001528A HUP0001528A HUP0001528A2 HU P0001528 A2 HUP0001528 A2 HU P0001528A2 HU 0001528 A HU0001528 A HU 0001528A HU P0001528 A HUP0001528 A HU P0001528A HU P0001528 A2 HUP0001528 A2 HU P0001528A2
Authority
HU
Hungary
Prior art keywords
sulfonylurea
glitazone
diabetes
combinations
therapy
Prior art date
Application number
HU0001528A
Other languages
English (en)
Inventor
Randall W. Whitcomb
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP0001528A2 publication Critical patent/HUP0001528A2/hu
Publication of HUP0001528A3 publication Critical patent/HUP0001528A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A jelen találmány diabéteszellenes szulfonil-karbamid vegyületek ésglitazon vegyületek kombinációjára, és ilyen kombinációk diabéteszkezelésére történő alkalmazására vonatkozik. A II típusú diabéteszt azinzulinrezisztencia mellett főként a glükóz stimulusra adott csökkenthasnyálmirigy válasz jelzi. Az inzulinrezisztencia javítása - egyglitazon vegyület adagolásával - nagy előnnyel jár, amikor egyfolyamatban levő, inzulinfelszabadulás stimulálására alkalmas (példáulszulfonilkarbamid), terápiával kapcsolják össze. A glitazon ésszulfonilkarbamid kombinációs terápia biztonságosnak és jóltorelálhatónak mutatkozik és a glikémiás kontrollban szignifikáns ésszinergetikus javulást eredményezhet. A szulfonil-karbamid maximálisdózisaival kezelt betegeket nem szabad glitazon monoterápiáraátállítani. A monoterápiát, amennyiben javallott, csak a szulfonil-karbamid dózis lefelé titrálásával szabad elérni. A vizsgálateredményeinek alkalmazása nem korlátozódhat olyan betegekre, akikesetében a maximális dózisú szulfonil-karbamid terápia nem hatásos,hanem a szulfonil-karbamid kisebb dózisaival kezelt betegekre iskiterjeszthető. Ó
HU0001528A 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergic combinations for diabetes HUP0001528A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (2)

Publication Number Publication Date
HUP0001528A2 true HUP0001528A2 (hu) 2000-11-28
HUP0001528A3 HUP0001528A3 (en) 2000-12-28

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001528A HUP0001528A3 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergic combinations for diabetes

Country Status (29)

Country Link
US (2) US5859037A (hu)
EP (1) EP0957923A1 (hu)
JP (1) JP2001512478A (hu)
KR (1) KR20000071179A (hu)
CN (1) CN1244801A (hu)
AR (1) AR011829A1 (hu)
AU (1) AU741215B2 (hu)
BG (1) BG103671A (hu)
BR (1) BR9714505A (hu)
CA (1) CA2272478A1 (hu)
CZ (1) CZ289299A3 (hu)
EA (1) EA199900725A1 (hu)
EE (1) EE9900345A (hu)
GT (1) GT199800037A (hu)
HN (1) HN1997000167A (hu)
HU (1) HUP0001528A3 (hu)
IL (1) IL130027A (hu)
IS (1) IS5058A (hu)
NO (1) NO993982L (hu)
NZ (1) NZ336002A (hu)
PA (1) PA8447401A1 (hu)
PE (1) PE74399A1 (hu)
PL (1) PL335166A1 (hu)
SK (1) SK111899A3 (hu)
SV (1) SV1998000010A (hu)
TR (1) TR199902033T2 (hu)
UY (1) UY24893A1 (hu)
WO (1) WO1998036755A1 (hu)
ZA (1) ZA981343B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
NZ501163A (en) * 1997-06-18 2002-02-01 Smithkline Beecham P Treatment of diabetes with thiazolidinedione and sulphonylurea (glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide
BR9810172A (pt) * 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e metformina
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
KR100689943B1 (ko) * 1998-12-24 2007-03-08 메타베이시스 테라퓨틱스, 인크. 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
CA2367955C (en) * 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
DK1145717T3 (da) 2000-04-13 2004-08-02 Pfizer Prod Inc Synergistisk virkning af glyburid og milrinon
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
WO2005041962A1 (en) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
AU2006289259A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
CA2633149C (en) 2005-12-22 2015-06-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
KR20200022525A (ko) * 2008-12-04 2020-03-03 충시 위 고투과력을 가진 조성물 및 이의 적용
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
CN103025334B (zh) 2010-05-24 2016-03-16 澳星医疗私人有限公司 抗糖尿病组合物和方法
KR102072322B1 (ko) 2011-01-19 2020-02-03 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 장치 및 방법
CN104244958B (zh) 2011-11-23 2017-11-17 澳星医疗私人有限公司 改进的协同抗糖尿病组合物
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
WO2015077571A1 (en) 2013-11-22 2015-05-28 Fractyl Laboratories, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
KR102086184B1 (ko) 2012-02-27 2020-03-06 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
KR102231179B1 (ko) 2012-04-19 2021-03-22 프랙틸 래브러토리스 인코포레이티드 조직 팽창 디바이스들, 시스템들, 및 방법들
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
US20230139684A1 (en) * 2019-11-22 2023-05-04 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AU5590898A (en) 1998-09-09
PL335166A1 (en) 2000-04-10
US5972973A (en) 1999-10-26
ZA981343B (en) 1998-11-16
BR9714505A (pt) 2000-03-21
CA2272478A1 (en) 1998-08-27
PE74399A1 (es) 1999-08-20
IL130027A0 (en) 2000-02-29
EP0957923A1 (en) 1999-11-24
EA199900725A1 (ru) 2000-04-24
TR199902033T2 (xx) 2000-02-21
US5859037A (en) 1999-01-12
JP2001512478A (ja) 2001-08-21
SK111899A3 (en) 2000-09-12
IS5058A (is) 1999-05-27
UY24893A1 (es) 1998-07-10
NZ336002A (en) 2002-03-28
AU741215B2 (en) 2001-11-29
PA8447401A1 (es) 2001-12-14
KR20000071179A (ko) 2000-11-25
GT199800037A (es) 1999-08-12
AR011829A1 (es) 2000-09-13
BG103671A (en) 2000-04-28
NO993982D0 (no) 1999-08-18
CZ289299A3 (cs) 1999-11-17
HN1997000167A (es) 1999-02-09
NO993982L (no) 1999-08-18
SV1998000010A (es) 1999-02-02
EE9900345A (et) 2000-02-15
HUP0001528A3 (en) 2000-12-28
IL130027A (en) 2005-09-25
CN1244801A (zh) 2000-02-16
WO1998036755A1 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
HUP0001528A2 (hu) Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére
ATE344023T1 (de) Transdermales therapeutisches pflaster mit capsaicin und seinen analogen
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
BR0015295A (pt) Formulação e método antidiabético
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BRPI0502691A (pt) composição farmacêutica para o controle da glicose no sangue de pacientes com diabetes tipo 2
MY155270A (en) Use of glp-1 or analogs in treatment of stroke
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
GR3032307T3 (en) Site-directed mutagenesis modified glycoprotein hormones and methods of use.
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
KR890004690A (ko) 당뇨병의 치료를 위한 베자피브레이드의 용도
WO2002058720A3 (en) Angiogenically effective unit dose of fgf-2 and method of use
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
AU6102801A (en) Method of preventing or treating diabetes
KR900701311A (ko) 재조합 사람 α-인터페론을 병소내로 투여하여 편평세포 암을 치료하는 방법
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
Ignatov et al. The analgetic activity of antidepressants and their influence on the pain-relieving effect of acupuncture
Walling Adolescent diabetes and use of insulin-like growth-factor-1.
Klinghardt BDORT and the subconscious mind
ATE328604T1 (de) Verwendung von wachstumshormon in niederen dosen
姚尊华 et al. OBSERVATION ON 52 CASES OF PARALYSIS OF COMMON PERONEAL NERVE TREATED BY ACUPUNCTURE AND PLUM-BLOSSOM NEEDLING
陈克勤 Personal experience with acupuncture therapy